# Logos Capital

> Logos Capital is a VC fund in Miami backing Biotechnology, Health Care and Therapeutics. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Miami, United States
- Total investments: 7
- Last investment: Aug 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/logos-capital
- X (Twitter): https://twitter.com/LOGOSCAPITAL
- Website: https://www.logoscapital.io
- Facebook: https://www.facebook.com/logoscapitalgroup

Logos Capital is an impact investment firm focused on creating financial solutions.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Health Care | 2 | 29% |
| Therapeutics | 2 | 29% |
| Medical | 1 | 14% |
| Biopharma | 1 | 14% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 43% |
| Seed | 1 | 14% |
| Series A | 1 | 14% |
| Post-IPO Equity | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 57% |
| Canada | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Expedition Therapeutics | Expedition Therapeutics operates as an unincorporated association. | $115M | Series B | Aug 05, 2026 |  |
| Beacon Biosignals | Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $11M | Series B | Apr 06, 2026 |  |
| Diagonal Therapeutics | Diagonal Therapeutics is a biotechnology startup that is pioneering a novel technique to finding and producing agonist antibodies. Diagonal Therapeutics platform combines novel computational and experimental methodologies to solve the traditional obstacles associated with agonist antibody drug development. | $125M | Series B | Jan 08, 2026 |  |
| SeraGene Therapeutics | SeraGene Therapeutics is a biotechnology company that offers treatment for coagulation disorders through nanomedicine technologies and RNA. |  | Seed | Nov 19, 2025 |  |
| Beacon Biosignals | Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $86M | Series B | Nov 13, 2025 |  |
| Expedition Therapeutics | Expedition Therapeutics operates as an unincorporated association. | $165M | Series A | Oct 09, 2025 |  |
| Spyre Therapeutics | Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies with the potential to revolutionize the treatment of inflammatory bowel disease (IBD). | $180M | Post-IPO Equity | Mar 18, 2024 |  |

7 of 7 investments shown.

## Co-investors
- [Innoviva](https://shizune.co/investors/profile/innoviva) — VC Fund, 3 deals together
- [Sanofi Ventures](https://shizune.co/investors/profile/sanofi-genzyme-bioventures) — VC Fund, 3 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 2 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 2 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 2 deals together
- [Dawn Biopharma](https://shizune.co/investors/profile/dawn-biopharma) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Logos Capital invest in?

Logos Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Logos Capital last invest?

The most recent investment recorded for Logos Capital closed in Aug 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co